GlassScriptPhysician profile
Karen S Lyons
NPI 1871560755
$2,758.00
in general payments reported to CMS, 2019-2025
22 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $57.27 · 2021: $549 · 2022: $744 · 2023: $324 · 2024: $630 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $1,051.14 | 2020-2024 | Ova1 |
| Abbvie INC. | $335.20 | 2019-2025 | |
| Biogen, INC. | $245.00 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $148.97 | 2021-2023 | Slynd |
| Pfizer INC. | $129.76 | 2019-2025 | |
| Organon LLC | $127.25 | 2021-2024 | |
| Allergan, INC. | $118.59 | 2019 | |
| Hologic Sales and Service, LLC | $110.35 | 2021-2023 | Aptima |
| Myovant Sciences INC. | $98.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.68 | 2019-2023 | Gardasil 9 |
| Daiichi Sankyo INC. | $62.36 | 2019-2022 | |
| Coopersurgical, INC. | $52.44 | 2021-2024 | Paragard T 380a |
| Stryker Corporation | $49.54 | 2023 | Spy-Phi System |
| Amag Pharmaceuticals, INC. | $28.00 | 2019 | |
| Sage Therapeutics, LLC | $17.85 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $17.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.45 | 2022 | |
| Millicent US INC | $14.12 | 2025 | Intrarosa |
| Evofem Biosciences, INC. | $13.49 | 2021 | |
| Novo Nordisk INC | $12.73 | 2021 | |
| Amgen INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.